company background image

Rapid Dose Therapeutics CNSX:DOSE Stock Report

Last Price


Market Cap







05 Aug, 2022


Company Financials
DOSE fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health4/6

DOSE Stock Overview

Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada.

Rapid Dose Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Rapid Dose Therapeutics
Historical stock prices
Current Share PriceCA$0.10
52 Week HighCA$0.69
52 Week LowCA$0.08
1 Month Change-50.00%
3 Month Change-65.52%
1 Year Change-83.33%
3 Year Change-85.91%
5 Year Changen/a
Change since IPO-88.24%

Recent News & Updates

Shareholder Returns

DOSECA Life SciencesCA Market

Return vs Industry: DOSE underperformed the Canadian Life Sciences industry which returned -21.3% over the past year.

Return vs Market: DOSE underperformed the Canadian Market which returned -1.7% over the past year.

Price Volatility

Is DOSE's price volatile compared to industry and market?
DOSE volatility
DOSE Average Weekly Movement29.4%
Life Sciences Industry Average Movement11.6%
Market Average Movement10.9%
10% most volatile stocks in CA Market19.4%
10% least volatile stocks in CA Market4.4%

Stable Share Price: DOSE is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 29% a week.

Volatility Over Time: DOSE's weekly volatility has increased from 18% to 29% over the past year.

About the Company

n/an/aMark Upsdell

Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release active ingredients into the blood stream, such as pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in the system; and QuickStrip sleep that delivers melatonin in the system. The company also provides product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries.

Rapid Dose Therapeutics Fundamentals Summary

How do Rapid Dose Therapeutics's earnings and revenue compare to its market cap?
DOSE fundamental statistics
Market CapCA$10.53m
Earnings (TTM)-CA$2.04m
Revenue (TTM)CA$1.05m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DOSE income statement (TTM)
Cost of RevenueCA$283.05k
Gross ProfitCA$763.03k
Other ExpensesCA$2.81m

Last Reported Earnings

Nov 30, 2021

Next Earnings Date


Earnings per share (EPS)-0.019
Gross Margin72.94%
Net Profit Margin-195.24%
Debt/Equity Ratio17.4%

How did DOSE perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is DOSE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DOSE?

Other financial metrics that can be useful for relative valuation.

DOSE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue11.3x
Enterprise Value/EBITDA-4.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does DOSE's PS Ratio compare to its peers?

DOSE PS Ratio vs Peers
The above table shows the PS ratio for DOSE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average3.2x
IOT Innovotech
IPA ImmunoPrecise Antibodies
GRIN Grown Rogue International
AYUR Ayurcann Holdings
DOSE Rapid Dose Therapeutics

Price-To-Sales vs Peers: DOSE is expensive based on its Price-To-Sales Ratio (10.1x) compared to the peer average (3.2x).

Price to Earnings Ratio vs Industry

How does DOSE's PE Ratio compare vs other companies in the North American Life Sciences Industry?

Price-To-Sales vs Industry: DOSE is expensive based on its Price-To-Sales Ratio (10.1x) compared to the North American Life Sciences industry average (5.3x)

Price to Sales Ratio vs Fair Ratio

What is DOSE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DOSE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate DOSE's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of DOSE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate DOSE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate DOSE's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Rapid Dose Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Rapid Dose Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Examine Rapid Dose Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Rapid Dose Therapeutics competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Rapid Dose Therapeutics performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: DOSE is currently unprofitable.

Growing Profit Margin: DOSE is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: DOSE is unprofitable, but has reduced losses over the past 5 years at a rate of 23.5% per year.

Accelerating Growth: Unable to compare DOSE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DOSE is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (16.5%).

Return on Equity

High ROE: DOSE has a negative Return on Equity (-58.49%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Rapid Dose Therapeutics's financial position?

Financial Health Score


Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: DOSE's short term assets (CA$1.1M) do not cover its short term liabilities (CA$1.9M).

Long Term Liabilities: DOSE's short term assets (CA$1.1M) exceed its long term liabilities (CA$443.9K).

Debt to Equity History and Analysis

Debt Level: DOSE's net debt to equity ratio (14.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if DOSE's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DOSE has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: DOSE is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.

Discover healthy companies


What is Rapid Dose Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate DOSE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DOSE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DOSE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DOSE's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as DOSE has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Mark Upsdell





Mr. Mark Andrew Upsdell is the Chief Executive Officer and Director of Rapid Dose Therapeutics Corp. since May 03, 2017 and he serves as its Chairman. He served as President of Rapid Dose Therapeutics Corp...

CEO Compensation Analysis

Compensation vs Market: Mark's total compensation ($USD77.59K) is below average for companies of similar size in the Canadian market ($USD186.69K).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: DOSE's management team is considered experienced (3.9 years average tenure).

Board Members

Experienced Board: DOSE's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.8%.

Top Shareholders

Company Information

Rapid Dose Therapeutics Corp.'s employee growth, exchange listings and data sources

Key Information

  • Name: Rapid Dose Therapeutics Corp.
  • Ticker: DOSE
  • Exchange: CNSX
  • Founded: NaN
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$10.533m
  • Shares outstanding: 105.33m
  • Website:


  • Rapid Dose Therapeutics Corp.
  • 1121 Walkers Line
  • Unit 3A
  • Burlington
  • Ontario
  • L7N 2G4
  • Canada


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/05 00:00
End of Day Share Price2022/08/05 00:00
Annual Earnings2021/02/28

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.